Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Highly Potent, Selective, Biostable, and Cell-Permeable Cyclic d-Peptide for Dual-Targeting Therapy of Lung Cancer.

Journal of the American Chemical Society - 27 Apr 2022

Zhou Yunjiang, Zou Yunting, Yang Mei, Mei Shuang, Liu Xiaohao, Han Huiyun, Zhang Chang-Dong, Niu Miao-Miao

Abstract excerpt

The application of peptide drugs in cancer therapy is impeded by their poor biostability and weak cell permeability. Therefore, it is imperative to find biostable and cell-permeable peptide drugs for cancer treatment. Here, we identified a potent, selective, biostable, and cell-permeable cyclic d-peptide, NKTP-3, that targets NRP1 and KRASG12D using structure-based virtual screening. NKTP-3 exhibited strong...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Peptides

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 35417174
DOI: 10.1021/jacs.1c12075

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Highly Potent, Selective, Biostable, and Cell-Permeable Cyclic d-Peptide for Dual-Targeting Therapy of Lung Cancer.PMID 35417174Read ↗

Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo.Semantic proximity Read ↗

Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors.Semantic proximity Read ↗

Design and investigation of interactions of novel peptide conjugates of purine and pyrimidine derivatives with EGFR and its mutant T790M/L858R: an in silico and laboratory study.Semantic proximity Read ↗

Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma.Semantic proximity Read ↗

Precision medicine by designer interference peptides: applications in oncology and molecular therapeuticsSemantic proximity Read ↗

CAR-NK cells with dual targeting of PD-L1 and MICA/B in human lung cancer H1299 cell tumor modelSemantic proximity Read ↗

Computational study of novel natural inhibitors targeting Kirsten rat sarcoma viral oncogene homolog G12C.Semantic proximity Read ↗

Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

In-silico design of peptide inhibitors of K-Ras target in cancer disease.Semantic proximity Read ↗

Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.Semantic proximity Read ↗

Selective targeting of oncogenic KRAS G12D using peptide nucleic acid oligomers attached to cell-penetrating peptidesSemantic proximity Read ↗

Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signalingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.